Current Status of Diagnosis, Treatment and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis (IPFLife)

Chu Hongling

Status: Invitation-only

Conditions: Idiopathic Pulmonary Fibrosis

Treatments: Other: No intervention

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT06629623

M2024203

Details and patient eligibility

About

The goal of this observational study is to explore current status of diagnosis, treatment and quality of life for patients with idiopathic pulmonary fibrosis. It aims to integrate qualitative and quantitative data to describe the distribution of perspective, experience, patient journey, treatment, expectation and quality of life for patients with idiopathic pulmonary fibrosis.

Participants will be invited to participate the interview, and answer quantitative survey questions about their quality of life.

Full description

Idiopathic pulmonary fibrosis (IPF) is a rare, progressive, fibrotic interstitial lung disease of unknown aetiology primarily affecting middle-aged and elderly patients, more men than women. Median survival is 3∼5 years from the time of diagnosis. The prognosis is worse than for most common malignancies. However, patients' experiences, quality of life and needs during the disease course, have not been adequately investigated, which leads a lack of evidence to support the priority of treatment or drug development.

This study plans to conduct an mixed methods research to integrate qualitative and quantitative data to explore the perspective, experience, patient journey, treatment, expectation and quality of life for patients with idiopathic pulmonary fibrosis. For qualitative interview, there are 50 patients with idiopathic pulmonary fibrosis, and 15 physicians will be interviewed. For quantitative survey, there are 245 patients with idiopathic pulmonary fibrosis will be involved.

Enrollment: 310 estimated patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• IPF patients who are diagnosed according to international guidelines.
• Physicians who are clinical experts with extensive experience in the treatment of IPF.

Exclusion criteria

• The patient is unable to express his/her opinion clearly.

Trial design

310 participants in 1 patient group

Patients with IPF

Treatment:

Other: No intervention